American Century Companies Boosts Incyte Stake by 468%

Investment firm increases position in biopharmaceutical company in third quarter

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

American Century Companies Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY) by 468.3% in the third quarter, according to the company's most recent filing with the Securities and Exchange Commission. The firm now owns 444,193 shares of the biopharmaceutical company's stock, up from 78,161 shares previously.

Why it matters

The significant increase in American Century's stake in Incyte reflects the investment firm's confidence in the biopharmaceutical company's growth potential. Incyte is known for its flagship product Jakafi, a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

The details

American Century Companies purchased an additional 366,032 shares of Incyte in the third quarter, bringing its total position to 444,193 shares. This represents approximately 0.23% of Incyte's outstanding shares, valued at $37.7 million as of the end of the quarter. The investment firm cited Incyte's promising pipeline of oncology and inflammation therapies as a key factor in its decision to increase its stake.

  • American Century Companies increased its Incyte position in the third quarter of 2026.

The players

American Century Companies Inc.

An investment management firm that oversees over $200 billion in assets for individual and institutional clients.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation, known for its flagship product Jakafi.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in American Century's Incyte position suggests the investment firm sees significant long-term growth potential in the biopharmaceutical company's pipeline and product portfolio, particularly its lead drug Jakafi. This reflects broader investor confidence in Incyte's ability to continue expanding its footprint in the oncology and inflammation treatment markets.